Three Firms Sign Up With MPP For Long-Acting Cabotegravir
Aurobindo, Cipla And Viatris’s Mylan Agree Deal To Produce HIV PrEP Treatment
Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – have signed licensing agreements with the Medicines Patent Pool that will allow them to produce versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis.
